Scientific Reports (Nov 2023)

Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave

  • Yun Shan Goh,
  • Siew-Wai Fong,
  • Matthew Zirui Tay,
  • Angeline Rouers,
  • Zi Wei Chang,
  • Jean-Marc Chavatte,
  • Pei Xiang Hor,
  • Chiew Yee Loh,
  • Yuling Huang,
  • Yong Jie Tan,
  • Bei Wang,
  • Eve Zi Xian Ngoh,
  • Siti Nazihah Mohd Salleh,
  • Raphael Tze Chuen Lee,
  • Georgina Lim,
  • NCID Study Group,
  • COVID-Study Group,
  • Sebastian Maurer-Stroh,
  • Cheng-I Wang,
  • Yee‐Sin Leo,
  • Raymond T. P. Lin,
  • Meng Chon Lam,
  • David C. Lye,
  • Barnaby Edward Young,
  • Lisa F. P. Ng,
  • Laurent Renia

DOI
https://doi.org/10.1038/s41598-023-46800-x
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Identification of the risk factors and the high-risk groups which are most vulnerable is critical in COVID-19 disease management at a population level. Evaluating the efficacy of vaccination against infections is necessary to determine booster vaccination strategies for better protection in high-risk groups. In this study, we recruited 158 mRNA-vaccinated individuals during the Delta wave of SARS-CoV-2 infections in Singapore and examined the antibody profiles of infected individuals. We found that, despite high exposure due to communal living conditions in proximity, 4% of individuals (6/158) had PCR-confirmed infections and 96% (152/158) remained uninfected. Time-course analysis of the antibody profile at the start and the end of quarantine period showed Delta-specific boosting of anti-spike antibody response in 57% of the uninfected individuals (86/152). In the remaining 43% of the uninfected individuals (66/152) with no Delta-specific antibody boost, we found a higher Delta-specific antibody response at the start of quarantine period, which correlated with higher Delta pseudovirus neutralizing capacity. Our findings indicate that a higher basal variant-specific antibody response in the mRNA-vaccinated individuals contributes to better protection against infections by the new emerging SARS-CoV-2 variants.